Event Information
Event Topic:
GATT Technologies – the Next Frontier in Surgical Management
Event Description:
Significant unmet needs exist in preventing uncontrolled surgical bleeding, and this need is expected to increase with the global increase in surgical procedures and the introduction of robotic surgery devices over the next decade. Large surgical blood losses are frequent and associated with higher mortality, longer hospitalizations and more frequent reoperations, thus imposing an increasing burden on society. GATT Technologies’ hemostats and sealants focus on controlling severe surgical bleedings as well as preventing and treating organ leakages. Leveraging its patented technology, the Company has developed a synthetic surgical and sealant platform with the potential to become a superior alternative to the current fibrin and PEG-polymer based solutions in terms of speed, efficacy and cost. Currently, the Company is focusing on moving the GATT-Patch, a fast hemostatic sealing patch to be used in general surgery, into clinical trials in Europe and the United States. Additionally, it is further developing its other pipeline products including GATT-Powder (hemostat, laparoscopic use) and GATT-Tape (intestinal anastomotic leakage) and is assessing other potential applications based on its activated polyoxazoline technology such as uses in bone regeneration, anti-adhesion, vascular, and ophthalmological procedures.
Date/Time:
Date(s) - 08/04/20
8:30 am - 10:30 am
Event Location:
Zoom talk: https://us02web.zoom.us/j/85043660945: Webinar
Speaker Information
Event Speaker:
Vlad Hogenhuis, MD, MBA
Event Speaker Title:
Founder
Event Speaker Company:
Lapene Healthcare Consulting LLC
Event Speaker Bio:
Dr. Vlad Hogenhuis, MD, recently served as Chief Operating Officer of Ultragenyx with responsibilities for global commercial operations, business development, and manufacturing of medicines for patients with rare diseases. Before that, Dr. Hogenhuis served as Senior Vice President and Global Franchise Head, Specialty Pharmaceuticals of GlaxoSmithKline Plc., from December 2012 to September 2018. From 1994 to 2012, he served in leadership positions at Merck &Co in the US, China, and Europe, where he was responsible for managing the P&L of specialty and cardiovascular care medicines. He also served as a National Institutes of Health Fellow in Medical Decision Making at New England Medical Centre in Boston, and as a Naval Lieutenant Surgeon in the Royal Dutch Navy. Dr. Hogenhuis currently serves on the board of GATT Technologies B.V., a private company in the Netherlands developing novel surgical hemostats. He is also a board member of IHP Therapeutics, a private company based in San Francisco, developing a therapy for the treatment of COVID-19 slated to enter phase 3 later this year. He previously served as a member of the Board of Directors of Vision 2020, a global initiative for the elimination of avoidable blindness, a joint programme of the World Health Organization and the International Agency for the Prevention of Blindness. Dr. Hogenhuis received a M.D. degree in Medicine Cum Laude from the University of Leiden in the Netherlands. He received an M.B.A. from the Wharton School of Business at The University of Pennsylvania, Philadelphia.
Event Details
Cost:
$0
Add To Calendar
